New data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants
Data in JAMA show Menveo may provide infants protection against four of the most common meningococcal serogroups - A, C, W-135 and Y
11-Jan-2008 -
Menveo(TM) (MenACWY-CRM), a vaccine in development by Novartis, may protect infants using a schedule beginning at two months of age against four of the most common causes of meningococcal disease. According to the company, Menveo is the only meningococcal vaccine shown to generate protection ...
bacterial infections
clinical trials
dosing
+5